BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 10723140)

  • 1. p53-independent association between SV40 large T antigen and the major cytosolic heat shock protein, HSP90.
    Miyata Y; Yahara I
    Oncogene; 2000 Mar; 19(11):1477-84. PubMed ID: 10723140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP2E1 degradation by in vitro reconstituted systems: role of the molecular chaperone hsp90.
    Goasduff T; Cederbaum AI
    Arch Biochem Biophys; 2000 Jul; 379(2):321-30. PubMed ID: 10898951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Geldanamycin prevents nuclear translocation of mutant p53.
    Dasgupta G; Momand J
    Exp Cell Res; 1997 Nov; 237(1):29-37. PubMed ID: 9417863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Geldanamycin, an hsp90/GRP94-binding drug, induces increased transcription of endoplasmic reticulum (ER) chaperones via the ER stress pathway.
    Lawson B; Brewer JW; Hendershot LM
    J Cell Physiol; 1998 Feb; 174(2):170-8. PubMed ID: 9428803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of protein kinase activities associated with p53-large-T immune complexes from SV40-transformed rat cells.
    Müller E; Boldyreff B; Scheidtmann KH
    Oncogene; 1993 Aug; 8(8):2193-205. PubMed ID: 8393163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Ah receptor is a sensitive target of geldanamycin-induced protein turnover.
    Chen HS; Singh SS; Perdew GH
    Arch Biochem Biophys; 1997 Dec; 348(1):190-8. PubMed ID: 9390191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heat shock protein-90 (Hsp90) acts as a repressor of peroxisome proliferator-activated receptor-alpha (PPARalpha) and PPARbeta activity.
    Sumanasekera WK; Tien ES; Davis JW; Turpey R; Perdew GH; Vanden Heuvel JP
    Biochemistry; 2003 Sep; 42(36):10726-35. PubMed ID: 12962497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The stabilization mechanism of mutant-type p53 by impaired ubiquitination: the loss of wild-type p53 function and the hsp90 association.
    Nagata Y; Anan T; Yoshida T; Mizukami T; Taya Y; Fujiwara T; Kato H; Saya H; Nakao M
    Oncogene; 1999 Oct; 18(44):6037-49. PubMed ID: 10557093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased oncogenicity of subclones of SV40 large T-induced neuroectodermal tumor cell lines after loss of large T expression and concomitant mutation in p53.
    Salewski H; Bayer TA; Eidhoff U; Preuss U; Weggen S; Scheidtmann KH
    Cancer Res; 1999 Apr; 59(8):1980-6. PubMed ID: 10213510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A role for the Hsp90 molecular chaperone family in antigen presentation to T lymphocytes via major histocompatibility complex class II molecules.
    Rajagopal D; Bal V; Mayor S; George A; Rath S
    Eur J Immunol; 2006 Apr; 36(4):828-41. PubMed ID: 16552710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Geldanamycin, a heat shock protein 90-binding agent, disrupts Stat5 activation in IL-2-stimulated cells.
    Xu W; Yu F; Yan M; Lu L; Zou W; Sun L; Zheng Z; Liu X
    J Cell Physiol; 2004 Feb; 198(2):188-96. PubMed ID: 14603521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex.
    Xu W; Yuan X; Xiang Z; Mimnaugh E; Marcu M; Neckers L
    Nat Struct Mol Biol; 2005 Feb; 12(2):120-6. PubMed ID: 15643424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. pRb, Myc and p53 are critically involved in SV40 large T antigen repression of PDGF beta-receptor transcription.
    Uramoto H; Hackzell A; Wetterskog D; Ballági A; Izumi H; Funa K
    J Cell Sci; 2004 Aug; 117(Pt 17):3855-65. PubMed ID: 15265983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.
    Chiosis G; Caldas Lopes E; Solit D
    Curr Opin Investig Drugs; 2006 Jun; 7(6):534-41. PubMed ID: 16784024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of HSP90 function inhibited on the telomerase and P53 mutant in breast cancer cells].
    Li X; Deng HY
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Mar; 39(2):181-3. PubMed ID: 18630678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hsp90 inhibitors: small molecules that transform the Hsp90 protein folding machinery into a catalyst for protein degradation.
    Blagg BS; Kerr TD
    Med Res Rev; 2006 May; 26(3):310-38. PubMed ID: 16385472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Hsp90 function delays and impairs recovery from heat shock.
    Duncan RF
    FEBS J; 2005 Oct; 272(20):5244-56. PubMed ID: 16218955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer.
    Bagatell R; Khan O; Paine-Murrieta G; Taylor CW; Akinaga S; Whitesell L
    Clin Cancer Res; 2001 Jul; 7(7):2076-84. PubMed ID: 11448926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chaperone activation of the hepadnaviral reverse transcriptase for template RNA binding is established by the Hsp70 and stimulated by the Hsp90 system.
    Stahl M; Retzlaff M; Nassal M; Beck J
    Nucleic Acids Res; 2007; 35(18):6124-36. PubMed ID: 17804463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of SV40 large T antigen induced apoptosis by small T antigen.
    Kolzau T; Hansen RS; Zahra D; Reddel RR; Braithwaite AW
    Oncogene; 1999 Sep; 18(40):5598-603. PubMed ID: 10523837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.